Cargando…

Bone Marrow Mastocytosis: A Diagnostic Challenge

Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanotti, Roberta, Tanasi, Ilaria, Bernardelli, Andrea, Orsolini, Giovanni, Bonadonna, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037514/
https://www.ncbi.nlm.nih.gov/pubmed/33915965
http://dx.doi.org/10.3390/jcm10071420
_version_ 1783677161539895296
author Zanotti, Roberta
Tanasi, Ilaria
Bernardelli, Andrea
Orsolini, Giovanni
Bonadonna, Patrizia
author_facet Zanotti, Roberta
Tanasi, Ilaria
Bernardelli, Andrea
Orsolini, Giovanni
Bonadonna, Patrizia
author_sort Zanotti, Roberta
collection PubMed
description Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase levels, low BM mast cells (MC) burden, and an indolent clinical course. BMM shows a strong correlation with severe anaphylaxis, mainly due to an IgE-mediated allergy to bee or wasp venom and, less frequently, to unexplained (idiopathic) anaphylaxis. Furthermore, BMM is often associated with osteoporosis which could be the only presenting symptom of the disease. BMM is an undervalued disease as serum tryptase levels are not routinely measured in the presence of unexplained osteoporosis or anaphylaxis. Moreover, BMM patients are often symptom-free except for severe allergic reactions. These factors, along with typical low BM MCs infiltration, may contribute to physicians overlooking BMM diagnosis, especially in medical centers that lack appropriately sensitive diagnostic techniques. This review highlights the need for a correct diagnostic pathway to diagnose BMM in patients with suspected symptoms but lacking typical skin lesions, even in the case of normal serum tryptase levels. Early diagnosis may prevent potential life-threatening anaphylaxis or severe skeletal complications.
format Online
Article
Text
id pubmed-8037514
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80375142021-04-12 Bone Marrow Mastocytosis: A Diagnostic Challenge Zanotti, Roberta Tanasi, Ilaria Bernardelli, Andrea Orsolini, Giovanni Bonadonna, Patrizia J Clin Med Review Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase levels, low BM mast cells (MC) burden, and an indolent clinical course. BMM shows a strong correlation with severe anaphylaxis, mainly due to an IgE-mediated allergy to bee or wasp venom and, less frequently, to unexplained (idiopathic) anaphylaxis. Furthermore, BMM is often associated with osteoporosis which could be the only presenting symptom of the disease. BMM is an undervalued disease as serum tryptase levels are not routinely measured in the presence of unexplained osteoporosis or anaphylaxis. Moreover, BMM patients are often symptom-free except for severe allergic reactions. These factors, along with typical low BM MCs infiltration, may contribute to physicians overlooking BMM diagnosis, especially in medical centers that lack appropriately sensitive diagnostic techniques. This review highlights the need for a correct diagnostic pathway to diagnose BMM in patients with suspected symptoms but lacking typical skin lesions, even in the case of normal serum tryptase levels. Early diagnosis may prevent potential life-threatening anaphylaxis or severe skeletal complications. MDPI 2021-04-01 /pmc/articles/PMC8037514/ /pubmed/33915965 http://dx.doi.org/10.3390/jcm10071420 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zanotti, Roberta
Tanasi, Ilaria
Bernardelli, Andrea
Orsolini, Giovanni
Bonadonna, Patrizia
Bone Marrow Mastocytosis: A Diagnostic Challenge
title Bone Marrow Mastocytosis: A Diagnostic Challenge
title_full Bone Marrow Mastocytosis: A Diagnostic Challenge
title_fullStr Bone Marrow Mastocytosis: A Diagnostic Challenge
title_full_unstemmed Bone Marrow Mastocytosis: A Diagnostic Challenge
title_short Bone Marrow Mastocytosis: A Diagnostic Challenge
title_sort bone marrow mastocytosis: a diagnostic challenge
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037514/
https://www.ncbi.nlm.nih.gov/pubmed/33915965
http://dx.doi.org/10.3390/jcm10071420
work_keys_str_mv AT zanottiroberta bonemarrowmastocytosisadiagnosticchallenge
AT tanasiilaria bonemarrowmastocytosisadiagnosticchallenge
AT bernardelliandrea bonemarrowmastocytosisadiagnosticchallenge
AT orsolinigiovanni bonemarrowmastocytosisadiagnosticchallenge
AT bonadonnapatrizia bonemarrowmastocytosisadiagnosticchallenge